Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen Sacks 80 as Focus Turns to Nascent Pipeline

NEW YORK, June 19 - CuraGen has laid off 20 percent of its staff, or around 80- people, as it directs its focus on its pipeline of protein, antibody, and small molecule therapeutics, the company said today.


CuraGen said the move is intended to "shift resources from discovery-based processes to preclinical and clinical activities needed to advance CuraGen's ... pipeline of genomics-based therapeutics."


The firm also said it hopes the cash is saves - which the firm will disclose next month - will "strengthen" its genomics and proteomics chops and help its toxicogenomics and biomarker drug-discovery efforts.


CuraGen had its first IND approval this year, and the company said it plans to have two additional approvals next year. "This restructuring further focuses the company on creating value from its first mover advantage in genomics, concentrating the company's investments on preclinical and clinical efforts necessary to accelerate our most promising therapeutics," said Jonathan Rothberg,  Chief Executive Officer, president and chairman.


CuraGen said laid-off employees will be eligible for severance pay, extended benefits, and outplacement services, CuraGen said.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.